OBJECTIVE To determine the trough and two hour plasma levels of nevirapine, stavudine, and lamivudine when administered in fixed dose combinations (FDC). DESIGN Cross sectional. SETTING Tertiary care hospital in Northern India. PARTICIPANTS 79 HIV-infected children receiving antiretroviral therapy with FDCs for more than month. INTERVENTION Two-point sampling (0 and 2 hours after the mo...

BACKGROUND Predictors of response of chronic hepatitis B (CHB) to lamivudine therapy need better definition. Whether hepatitis B virus (HBV) genotypes could serve as such a predictor has not been well studied. AIM To study the association of HBV genotypes with the outcome of lamivudine treatment in patients with CHB. METHODS Seventy-six patients with CHB (45 HBeAg +ve) received lamivudine 1...

a simple, accurate and precise hptlc- densitometry method for the simultaneousdetermination of abacavir, lamivudine and zidovudine in pharmaceutical tablet has beendeveloped. separation of tablet components was performed on aluminum backed hptlc plates(silica gel 60 f254 20×20 cm with 0.2 mm thickness, camag, muttenz, switzerland ) usingmethanol : chloroform : acetonitrile (4 : 8 : 3 v/v). good...

The INNO-LiPA HBV DR v2 assay is designed to detect hepatitis B virus mutations conveying resistance to lamivudine and adefovir. Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier.

We describe 2 patients who were initially positive for antibodies to hepatitis B surface antigen and who experienced a strong and sudden increase of hepatitis B virus (HBV) replication during highly active antiretroviral therapy (HAART). We found that reactivation of HBV replication during HAART can occur independently of lamivudine resistance or withdrawal of lamivudine, and in spite of increa...

Materials and methods We performed a study in the National Institute for Infectious Diseases “Prof. Dr. Matei Bals”, Bucharest, Romania, randomizing patients between two groups initially: therapy with lamivudine 100 mg/day vs. standard of care (no antiviral therapy) and subsequently between three groups: lamivudine, standard of care and entecavir 0.5 mg/day, when this new analogue became availa...

Assessment of prevalence SARS-CoV-2 Infection in patients on anti-HBV (lamivudine) treatment: A questionnaire based survey - IJMMTD- Print ISSN No: 2581-4753 Online No:- 2581-4761 Article DOI 10.18231/j.ijmmtd.2021.005, IP International Journal Medical Microbiology and Tropical Diseases-IP Int J Med M

CONTEXT Raising the chemotherapy-induced HBV reactivation is parallel to the increment of chemotherapy treatments in breast cancer patients. This meta-analysis aims to evaluate the efficacy of prophylactic use of lamivudine in breast cancer patients with HBsAg positive during chemotherapy. EVIDENCE ACQUISITION MEDLINE, Pubmed, Ovid and Embase were used to search for clinical studies comparing...

BACKGROUND Entecavir is a potent and selective guanosine analogue with significant activity against hepatitis B virus (HBV). METHODS In this phase 3, double-blind trial, we randomly assigned 715 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had not previously received a nucleoside analogue to receive either 0.5 mg of entecavir or 100 mg of lamivudine once daily ...

Two phase I studies were conducted to assess the plasma pharmacokinetics of telbivudine and potential drug-drug interactions between telbivudine (200 or 600 mg/day) and lamivudine (100 mg/day) or adefovir dipivoxil (10 mg/day) in healthy subjects. Study drugs were administered orally. The pharmacokinetics of telbivudine were characterized by rapid absorption with biphasic disposition. The maxim...